Weight and BMI patterns in IBD patients on infliximab
Part of Digestive system, Hormones & metabolism clinical trials.
This study looks at how weight and body mass index (BMI) change in people with inflammatory bowel disease who are taking infliximab, and whether those changes affect treatment costs. It will help understand if weight affects how well the medicine works and what it costs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been taking infliximab (a biologic medicine for IBD) for at least 14 weeks.
- You must have completed the usual starting doses at weeks 0, 2, and 6.
- You may be on infliximab alone or with certain other IBD medicines (like aminosalicylates, prednisone, azathioprine, methotrexate).
- You cannot be taking infliximab with medicines like tacrolimus, cyclosporine, sirolimus, mycophenolate mofetil, another biologic, or tofacitinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether body weight or obesity changes how well treatment works for people with inflammatory bowel disease (IBD), which causes inflammation in the digestive tract. If you have IBD and are already on treatment, this trial may help doctors understand how to personalize care.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This study tracks how patients with Crohn's disease or ulcerative colitis respond to infliximab (a biologic medication) given as injections under the skin after an initial IV dose. Researchers want to understand which patients benefit most and for how long.
This study tests a medicine called infliximab, given as an injection under the skin, to see how the body processes it in people with inflammatory bowel disease (Crohn's disease or ulcerative colitis). It may help find the best dose for your condition.
This trial tests whether a person's genetic makeup affects how well infliximab works for treating Crohn's disease. It may help doctors predict which patients benefit most from this medication.
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
Hear when a new Inflammatory Bowel Diseases Weight Changes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.